Previous studies have provided evidence that multiple systemic effects of SGLT2 inhibition, including decreased blood pressure, natriuresis, glycosuria, decreased extracellular fluid volume, and improved kidney function, may provide beneficial cardiovascular effects in patients with HF, with or without diabetes (5, 50). Here, SLC5A2 is linked to diabetes mellitus.